Clinical Trial Update: Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating pembrolizumab in intermediate- to high-risk smoldering multiple myeloma. The trial is active but not recruiting, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Smoldering Plasma Cell Myeloma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-03-20